8:55am ET
Investing
Huge Insider Buying From Buffett, an NFL Team Owner, a New CEO
Warren Buffett boosts his stake in this tracking stock again, plus notable insider buying from an NFL team owner and a new CEO.
Companies
/Healthcare
Nkarta Inc
$2.77
▲ $0.07 (+2.41%) today
Markets closed · 6:01am ET
Today · % change
Fundamentals
Market Cap
$193.4M
Revenue (TTM)
$385
EPS (TTM)
$-1.58
52-Week Range
$2 – $4
Street Target
$10.83
About Nkarta
Nkarta Inc is a pioneering biopharmaceutical firm focused on the development of innovative cell therapies for cancer patients. With a keen eye on cellular immunotherapy, Nkarta harnesses chimeric antigen receptors to empower lymphocytes to detect and attack tumor cells. Its leading projects, NKX101 and NKX019, are trailblazing treatments targeting acute myeloid leukemia and B cell malignancies, respectively. Founded in 2015 and based in South San Francisco, California, Nkarta stands at the forefront of cancer therapy research, collaborating with industry leaders like CRISPR Therapeutics AG to revolutionize patient care.
